摘要
目的探讨参麦注射液对外伤性蛛网膜下腔出血(tSAH)后脑血管痉挛(CVS)的治疗效果及其对血浆和脑脊液内皮素-1(ET-1)的影响。方法将合并tSAH的颅脑损伤患者63例按随机数字表法分为参麦组(33例)和对照组(30例)。参麦组在常规治疗基础上加用参麦注射液,对照组采用常规治疗。用放射免疫分析法分别测定血浆和脑脊液ET-1浓度,经颅多普勒超声连续检测伤后大脑中动脉血流速度(Vm)变化并评价CVS程度,记录6个月后GOS昏迷预后评分。结果参麦组患者血浆和脑脊液ET-1值在1周后较对照组显著降低(P<0.01);Vm在6天后较对照组显著降低(P<0.01);轻度CVS检出率显著低于对照组(P<0.05)。结论参麦注射液可通过降低ET-1水平改善tSAH患者CVS状态,但不能改善患者最终预后。
Objective To investigate of Shenmai injection for cerebral vasospasm （CVS） after traumatic subarachnoid hemorrhage （tSAH） and its relation to ET- 1 levels in plasma and cerebrospinal fluid （CSF）. Methods Sixty three tSAH patients were randomly assigned to receive conventional treatment and Shenmai injection（Shenmai group, n=33） or conventional treatment only （control group, n=30）. The levels of plasma and CSF ET- 1 were measured by raidoimmunoassay. Mean middle cerebral artery flow velocity（Vm） was detected by transcranial Doppler and the Glasgow Outcome Score （GOS） at 6 month after treatment was recorded. Results The levels of plasma and CSF ET- 1 in Shenmai group were significantly lower than those control group after one week （P〈0.01）. Vm in Shenmai group was significantly slower than that in control group after 6 days （P〈0.01）. The de-tection rate of mild CVS in Shenmai group was significantly lower than that in control group（P〈0.05）. Conclusion Shenmai injec-tion can improve cerebral vasospasm status in patients with tSAH, which is associated with the reduction of ET- 1 levels in plasma and CSF.
出处
《浙江医学》
CAS
2014年第4期271-273,277,共4页
Zhejiang Medical Journal
基金
浙江省医学会临床科研基金资助项目(2010ZYC-A38)
